Astellas Pharma Inc. (OTCMKTS:ALPMY) Short Interest Update

Astellas Pharma Inc. (OTCMKTS:ALPMY - Get Free Report) was the recipient of a significant growth in short interest in the month of March. As of March 31st, there was short interest totalling 60,400 shares, a growth of 144.5% from the March 15th total of 24,700 shares. Based on an average daily volume of 164,900 shares, the short-interest ratio is presently 0.4 days. Approximately 0.0% of the shares of the stock are sold short.

Astellas Pharma Price Performance

Shares of ALPMY stock traded up $0.14 during mid-day trading on Friday, hitting $9.35. 169,535 shares of the stock traded hands, compared to its average volume of 228,980. Astellas Pharma has a twelve month low of $8.37 and a twelve month high of $13.14. The company has a debt-to-equity ratio of 0.39, a quick ratio of 0.80 and a current ratio of 1.04. The company's 50-day simple moving average is $9.60 and its 200-day simple moving average is $10.12. The firm has a market cap of $16.92 billion, a price-to-earnings ratio of -42.50 and a beta of 0.31.

Astellas Pharma (OTCMKTS:ALPMY - Get Free Report) last released its earnings results on Tuesday, February 4th. The company reported $0.30 earnings per share (EPS) for the quarter. Astellas Pharma had a positive return on equity of 13.69% and a negative net margin of 3.10%. As a group, equities research analysts expect that Astellas Pharma will post 0.42 earnings per share for the current year.

About Astellas Pharma

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.